Articles

Biogen Faces Italian Antitrust Probe: What It Means for the Multiple Sclerosis Market

Biogen's Italian subsidiary and its US parent are under investigation by the Italian antitrust authority for alleged abuse of a dominant position in the multiple sclerosis market. This probe, stemming from concerns over drug pricing and market practices, could have significant repercussions for Biogen and the broader MS therapeutic area.

White House Taps Amazon, GoodRx to Expand TrumpRx Generic Drug Access

The White House has partnered with Amazon Pharmacy and GoodRx to significantly expand TrumpRx.gov, integrating discounts for hundreds of generic drugs to enhance patient access and affordability.

DCAT Week 2024: Strategic Imperatives for Pharma BD and Investors

DCAT Week 2024 convened leaders across the pharmaceutical manufacturing value chain. This article distills critical insights for business development teams and investors, focusing on regulatory shifts, supply chain resilience, and strategic partnership opportunities.

FDA Leadership Vacuum: Navigating Uncertainty for Pharmaceutical Business Development

Recent leadership changes at the FDA have created a vacuum, potentially impacting regulatory timelines and strategic decision-making for pharmaceutical companies. This analysis explores the implications for business development, regulatory affairs, and investment.

Supreme Court Upholds Medicare Drug Price Negotiation: Implications for Pharma

The Supreme Court has declined to hear appeals from several pharmaceutical companies challenging the Medicare drug price negotiation program. This decision allows the program to move forward, impacting future drug pricing strategies and market access for pharmaceutical companies.

Roche's Alecensa Secures Expanded Approval in Japan for ALK-Positive Lung Cancer

Roche has secured an expanded approval for Alecensa in Japan, broadening its therapeutic reach for patients with ALK-positive non-small cell lung cancer. This development underscores Roche's commitment to advancing targeted therapies in oncology.

Wave Life Sciences' Monthly Dosing Strategy for AATD: A Competitive Analysis

Wave Life Sciences is advancing its RNA editing therapy for Alpha-1 Antitrypsin Deficiency (AATD) with a novel monthly dosing strategy. This approach aims to significantly improve upon current weekly intravenous augmentation therapy, presenting new competitive dynamics and regulatory pathways for AATD treatments.

FDA Cracks Down on Illegal Tobacco Products Disguised as Everyday Items

The FDA has issued warning letters to eight retailers for selling unauthorized tobacco products designed to look like candy, breath strips, and cough drops. This action highlights regulatory scrutiny on products appealing to youth and posing ingestion risks.

Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD

Biogen faces scrutiny following recent Alzheimer's data releases and executive departures. This analysis explores the implications for pharmaceutical business development and investment strategies.

BMS-Hengrui $15B Deal: Strategic Implications for Pharma Executives

Bristol Myers Squibb's significant $15 billion partnership with Hengrui Pharma signals a strategic shift, leveraging China's R&D capabilities for early-stage assets. This deal offers valuable insights for pharmaceutical business development and investment teams.

Eli Lilly Dominates Pharma R&D Performance Rankings, Setting New Benchmarks

Eli Lilly has emerged as the top performer in recent pharmaceutical R&D rankings, excelling in both innovation and invention. This analysis delves into the specifics of these rankings and their strategic implications for the broader pharmaceutical industry.

TrumpRx Expands Generic Drug Offerings: Implications for Pharma BD and Investors

TrumpRx has significantly broadened its generic medicine catalog, adding over 600 new drugs to its platform. This strategic move aims to increase access to affordable medications and presents new considerations for pharmaceutical business development and investment strategies.

Immunovant's IMVT-1402 Shows Blockbuster Potential in Autoimmune Disease; Wave Life Sciences Advances RNA Editing

Immunovant's IMVT-1402 demonstrates significant promise in treating difficult-to-treat rheumatoid arthritis, positioning it as a potential blockbuster. Concurrently, Wave Life Sciences is making strides in RNA editing for rare diseases, highlighting innovation in genetic medicine.

Surgeon General's Warning on Children's Screen Time: A Pharma Industry Analysis

The U.S. Surgeon General has issued a public health advisory highlighting the risks of excessive screen time for children and adolescents. This analysis explores the downstream effects on the pharmaceutical sector.

Eli Lilly Acquires Engage Bio to Advance Non-Viral Genetic Medicines

Eli Lilly has acquired Engage Bio in a deal valued up to $202 million, significantly bolstering its capabilities in non-viral genetic medicines. The acquisition centers on Engage's proprietary Tethosome platform, designed to overcome key challenges in DNA delivery.

Retro Biosciences Secures $1.8 Billion Valuation in Landmark Longevity Funding Round

Retro Biosciences has achieved a $1.8 billion valuation after its latest fundraising round, signaling significant investor confidence in the longevity sector. This development presents key strategic considerations for pharmaceutical companies and regulatory bodies.

Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors

Recent leadership transitions at Amgen and Zai Lab signal potential shifts in strategic direction and operational focus. Understanding these changes is crucial for pharmaceutical business development, investment, and regulatory teams.

Eli Lilly's Strategic Vaccine Acquisitions: A New Era in Infectious Disease

Eli Lilly has strategically acquired three vaccine developers for up to $4 billion, significantly expanding its infectious disease pipeline. This move diversifies Lilly's portfolio and positions it for future growth in the vaccine market.

FDA Misses Electric Shock Ban Deadline, Advocates Voice Concerns

Disability advocates are speaking out after the FDA failed to meet its self-imposed deadline to ban the use of electrical shock devices on individuals with intellectual disabilities. This delay raises significant ethical and medical concerns.

HER2 Biology's Role in Advancing Next-Generation Cancer Therapies

Understanding HER2 biology is crucial for developing innovative, next-generation cancer treatments. This evolving knowledge is unlocking new therapeutic strategies and improving patient care.